Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pfizer and Moderna win FDA nod for XBB.1.5 COVID-19 vaccine boosters, but projected sales pale in comparison to 2022’s

By Brian Buntz | September 11, 2023

Pfizer-BioNTech-ModernaAs Pfizer and Moderna receive the FDA nod for COVID-19 boosters, their 2023 global sales projections appear to be just a fraction of the previous year’s. In 2022, Pfizer and its partner BioNTech jointly sold $56 billion worth of their Comirnaty COVID-19 vaccine, marking the best-selling drug of the year. Moderna’s Spikevax COVID-19 vaccine wasn’t far behind, registering sales of $18.4 billion, signifying the fifth best-selling drug.

After the FDA nod for COVID-19 boosters, market projections remain subdued

Demand for COVID-19 vaccines, however, appears to be relatively weak, a reality reflected in revenue guidance from Pfizer and Moderna. The former announced in its Q2 2023 revenue guidance that it projects its COVID-19 vaccine sales of approximately $13.5 billion — a 64% slide from its respective 2022 global sales of $37.8 billion. Meanwhile, Moderna expects its 2023 COVID-19 vaccine sales in the range of $6 billion to $8 billion.

A simple linear regression model reached similar projections — projecting $13.6 billion in cumulative vaccine sales for Pfizer and $7 billion for Moderna. The model considered global vaccination rates from Our World in Data, the U.S. Centers for Disease Control and Prevention (CDC) and previous  company financial reports. The model accounted for global vaccination rates, the trajectory of the pandemic, government policies, market competition, and projected hospitalizations.

The new monovalent boosters target the omicron XBB.1.5 subvariant. This particular subvariant of COVID-19, which evolved from the BA.2 omicron subvariant, has mutations that increase its transmissibility over older variants.

The bar graph below highlights the delta between the 2022 COVID-19 vaccine sales and the 2023 projections for Pfizer and Moderna. Sales figures are in billions of USD. Results show the tally from the linear regression model rather than the company’s own estimates mentioned above.

Vaccine makers face share price slides post-approval

Pfizer and Moderna both saw stock drops after announcing the approval of their latest COVID-19 vaccines. For example, Moderna’s share price fell 1.71% today to $105.80. COVID-19 vaccines is the company’s only commercialized product. On the other hand, Pfizer shares fell 0.91% today, bringing its closing price to $33.94.

Novavax, which is also developing a novel protein-based COVID-19 vaccine, saw a steeper tumble — almost 13% — as the FDA nod for Pfizer and Moderna gives them a head start in the market. The stock closed at $7.82, a far cry from its all-time high of $289.72 on February 12, 2021.

The company is planning to present vaccine data to a CDC advisory panel on Tuesday.

 


Filed Under: Drug Discovery and Development, Infectious Disease, Regulatory affairs
Tagged With: 2023 financial outlook, COVID-19 boosters, FDA authorization, Moderna, Pfizer, pharma industry trends, vaccine sales projections
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
Novel coronovirus
Advances in next generation vaccine development for SARS-CoV-2
Gay couple enjoying life together
World AIDS Day Summit & Celebration slated for early December
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE